MARKETS
RELIANCETCSHDFCBANKINFYICICIBANKSBINITCLTBHARTIARTLAXISBANKMARUTISUNPHARMA

Hexagon Nutrition Ltd.

HEXAGON · Pharmaceuticals & Drugs
₹61.36
▼ 3.83 (-5.88%)
Market dataas of 23 Oct 2026, 3:57 pm IST
52-week range · NSE21.6% below its high
Low ₹48.10High ₹78.25
27.6% above its low
Today’s range · NSE₹59.02 – ₹65.50
Low ₹59.02High ₹65.50
Opened at ₹65.50; 11.0% between low and high
P/E against its industry31% below the industry median
HEXAGON17.9
Industry median25.9
Pharmaceuticals & Drugs · median of profitable companies in the industry
Market cap₹679 Cr
Current price₹61.36
Volume · NSE12.68 L
52w High / Low · NSE₹78 / ₹48
Stock P/E17.9
Industry P/E25.9
Book value₹19.98
Dividend yield0.49%
ROCE22.8%
ROE18.8%
Debt / Equity0.13
EPS (TTM)₹3.43
Face value₹1

Price

Daily candles · NSE
▲ ₹10.7 (21.12%)over 1Y
50.060.070.080.01.1CrJun 26Jul 26Aug 26Sep 26Oct 26

What the numbers say

  • Low return on equity: 3-year ROE 13.6%.
  • Comfortable leverage: debt-to-equity of 0.13.
  • Sales compounded at 11.2% over 3 years.
  • Weak cash conversion (CFO/OP 0.48).
  • Trades below its industry P/E (17.9 vs 25.9).

Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.

  • Board Meeting

    Inter alia, to consider and take note of the following matters: 1. To take note of receipt of requisiOon le?er U/s 100(2) of the Companies Act, 2013 dated 24th September 2026 from Dr. Nikhil Arun Kelkar and Mr. Vikram Arun Kelkar, Promoters and Shareholders…

Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.

Profit & Loss · ₹ croreFY26FY25FY24FY23FY22
Net Sales383325298279271
Other income136734
Total Income395331305282275
Expenditure331284273256235
Operating Profit6547312640
Interest44432
Depreciation109887
Profit before tax513420932
Tax139749
Net Profit382412623
EPS (₹)3.431.751.100.512.11
Net margin %9.97.54.12.18.6

Consolidated figures, as filed with the exchanges. Newest year first.

Balance Sheet · ₹ croreFY26FY25FY24FY23FY22
Equity capital1111111111
Reserves210171153140136
Net worth221182164151147
Total sources247209191173169
Net block6464655655
Capital work in progress34247
Investments4641213224
Inventory8461798861
Debtors8260497456
Cash & bank1820242228
Book value (₹)19.9816.4514.7913.6413.33

Consolidated figures, as filed with the exchanges. Newest year first.

Cash Flow · ₹ croreFY26FY25FY24FY23FY22
From operations63823-011
From investing-6-224-19-21
From financing-0-19-19716
Net change in cash0-38-126
Free cash flow11627-19-10
Closing cash1615191123

Consolidated figures, as filed with the exchanges. Newest year first.

RatiosFY26FY25FY24FY23FY22
ROCE %22.817.411.16.219.4
ROE %18.814.17.83.917.1
PAT margin %9.67.34.12.18.6
EBIT margin %14.011.37.94.612.8
Debt / equity0.130.140.210.320.25
Current ratio3.383.502.981.932.19
Interest cover13.729.545.703.8215.14
Sales growth %17.89.16.92.828.1
Dividend per share (₹)0.300.000.000.000.15
Payout %8.70.00.00.07.1

Consolidated figures, as filed with the exchanges. Newest year first.

Frequently asked

Hexagon Nutrition Ltd. (HEXAGON) last traded at ₹61.36 on the NSE, down +5.88% on the session. Prices on this page are indicative and for information only.

Hexagon Nutrition Ltd. has traded between ₹48.10 and ₹78.25 over the last 52 weeks on the NSE.

Hexagon Nutrition Ltd. has a market capitalisation of about ₹679 crore.

Hexagon Nutrition Ltd. trades at a P/E of 17.9, against an industry P/E of 25.9.

Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for HEXAGON from the Labdhi app or web platform.

Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.

Who is actually trading it

Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Hexagon Nutrition Ltd..

Loading trading activity…

Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.

Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.

Figures are as reported by the company; consolidated where available. Errors and omissions excepted.

L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in